Near-term strategies for biotech drug developers facing shifting healthcare dynamics
A dynamic convergence of economic, legislative, scientific, and technological influences is molding the future of the healthcare industry – with implications for biotech companies. Healthcare environments are becoming increasingly complex as drug developers increasingly make the transition to next-generation therapeutics, driving demand for clinical innovation. Against this backdrop, the industry continues to pioneer new approaches to engaging with patients, clinical trial teams, and healthcare providers. During a recent panel discussion, Goldman Sachs and Parexel shared perspectives on emerging trends and high-level developments to help biotechs plan their short- and near-term strategies.
Get more insights from our recent panel discussion with Goldman Sachs, entitled “Decoding Healthcare’s Future: A comprehensive analysis of investment, clinical research and regulatory dynamics.”
The views and opinions expressed by the authors are their own and are for informational purposes only. They do not constitute a recommendation by Goldman Sachs, or Parexel, for you to take any action.
Related Insights
Article
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Article
Lessons from China and the United States on the use of RWE in regulatory submissions
Jul 19, 2021
Article
Three strategies for articulating a coherent product value story
Dec 18, 2021
Whitepaper
The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations
Mar 9, 2023
Video
Overcoming asset transfer challenges during a merger and acquisition (M&A)
Oct 20, 2021
Article
How emerging biotechs can enter the Chinese market and prosper
Jan 18, 2022
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Blog
Focusing on value drivers to reduce risk in early-stage drug development
Jan 6, 2025
Article
8 things you need to know about eCTDs in China
Jul 1, 2022
Webinar
Accelerated Early Phase Decision-Making – Insider Insights to Speed Development
Jan 7, 2025
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Related Insights
Article
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Article
Lessons from China and the United States on the use of RWE in regulatory submissions
Jul 19, 2021
Article
Three strategies for articulating a coherent product value story
Dec 18, 2021
Whitepaper
The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations
Mar 9, 2023
Video
Overcoming asset transfer challenges during a merger and acquisition (M&A)
Oct 20, 2021
Article
How emerging biotechs can enter the Chinese market and prosper
Jan 18, 2022
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Blog
Focusing on value drivers to reduce risk in early-stage drug development
Jan 6, 2025
Article
8 things you need to know about eCTDs in China
Jul 1, 2022
Webinar
Accelerated Early Phase Decision-Making – Insider Insights to Speed Development
Jan 7, 2025
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023